Clinical Trials

160 enrolled

Urinary Bladder Neoplasms

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT04557059 2026-04-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

Prostate Adenocarcinoma

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT06244004 2026-03-30

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

125 enrolled

Prostatic Neoplasms

NCT04879940 2026-03-23

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

17 enrolled

Prostatic Hyperplasia, Prostatic Neoplasms

NCT05656794 2026-03-23

CONSORT-PC

40 enrolled

Prostate Metastases

NCT06409910 2026-03-23

AMPORA

204 enrolled

Post-Operative Prostate Cancer

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

493 enrolled

Prostatic Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT07477626 2026-03-17

RADVAN

374 enrolled

Prostatic Neoplasms

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT07245745 2026-03-16

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

Phase NA Recruiting

188 enrolled

DermatologicGastrointestinalGenitourinary

Prostatic Neoplasms

NCT02439008 2026-03-13

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

Phase NA Terminated

28 enrolled

Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Colorectal Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

41 enrolled

Advanced Bladder Cancer

NCT04422132 2026-02-27

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

134 enrolled

Prostatic Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Wilms Tumor

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

72 enrolled

Phase NA Active not recruiting

Prostatic Neoplasms

NCT06037863 2026-02-23

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

168 enrolled

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT04983095 2026-02-17

METRO

Phase NA Recruiting

118 enrolled

Phase EARLY_PHASE1 Recruiting

Prostate Cancer Metastatic

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

20 enrolled

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

94 enrolled 13 charts

Prostatic Neoplasms

NCT01517451 2026-02-11

Radiation and Androgen Ablation for Prostate Cancer

Phase 1/2 Completed

45 enrolled 11 charts

Adenocarcinoma of the Prostate

NCT07202247 2026-02-04

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

60 enrolled

Prostatic Neoplasms

NCT04997018 2026-01-30

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

91 enrolled

Prostatic Neoplasms

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

64 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT07364071 2026-01-27

SENTRY

Phase 2 Not yet recruiting

150 enrolled

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

586 enrolled

Prostatic Neoplasms

NCT06391034 2026-01-07

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

161 enrolled

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Prostate Adenocarcinoma

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

234 enrolled

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT07268339 2025-12-05

TRAIN

328 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

110 enrolled

Oligometastatic Prostate Carcinoma

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

186 enrolled

Prostatic Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

95 enrolled

Urinary Bladder Neoplasms

NCT06150417 2025-11-12

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

200 enrolled

Prostatic Neoplasms

NCT01368588 2025-10-28

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

2,592 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3 Recruiting

1,273 enrolled

Prostatic Neoplasms

NCT05649943 2025-09-03

APPROACH

Phase NA Recruiting

566 enrolled